Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma

Nicolas Jacquelot, Jonathan M. Pitt, David P. Enot, Maria Paula Roberti, Connie P.M. Duong, Sylvie Rusakiewicz, Alexander M. Eggermont, Laurence Zitvogel

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

16 Citaten (Scopus)

Samenvatting

Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called “immune checkpoints”, which have now entered the oncotherapeutic armamentarium.

Originele taal-2Engels
Artikelnummere1299303
TijdschriftOncoImmunology
Volume6
Nummer van het tijdschrift8
DOI's
StatusGepubliceerd - 3 aug. 2017
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit